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Marine biogenics in sea spray 
aerosols interact with the mTOR 
signaling pathway
Jana Asselman  1, Emmanuel Van Acker1, Maarten De Rijcke2, Laurentijn Tilleman  3, 
Filip Van Nieuwerburgh  3, Jan Mees2, Karel A. C. De Schamphelaere1 & Colin R. Janssen1
Sea spray aerosols (SSAs) have profound effects on our climate and ecosystems. They also contain 
microbiota and biogenic molecules which could affect human health. Yet the exposure and effects of 
SSAs on human health remain poorly studied. Here, we exposed human lung cancer cells to extracts 
of a natural sea spray aerosol collected at the seashore in Belgium, a laboratory-generated SSA, the 
marine algal toxin homoyessotoxin and a chemical inhibitor of the mammalian target of rapamycin 
(mTOR) pathway. We observed significant increased expression of genes related to the mTOR pathway 
and Proprotein convertase subtilisin/kexin type 9 (PCSK9) after exposure to homoyessotoxin and the 
laboratory-generated SSA. In contrast, we observed a significant decrease in gene expression in the 
mTOR pathway and of PCSK9 after exposure to the natural SSA and the mTOR inhibitor, suggesting 
induction of apoptosis. Our results indicate that marine biogenics in SSAs interact with PCSK9 and 
the mTOR pathway and can be used in new potential pharmaceutical applications. Overall, our results 
provide a substantial molecular evidence base for potential beneficial health effects at environmentally 
relevant concentrations of natural SSAs.
Oceans and seas contain a variety of biogenic or naturally produced molecules that become airborne via sea spray 
aerosolization1–3. In addition to bacteria, which are well-known producers of biogenics, many phytoplankton spe-
cies also produce a wide range of bioactive molecules such as vitamins, pigments, polyphenolics and phycotoxins, 
which are potent organic compounds4,5. Phycotoxins have primarily been studied in the context of harmful algal 
blooms, in which they can be present at detrimental concentrations4,6. Phycotoxins can be found in seafood and 
often lead to intoxication or shellfish poisoning due to its consumption4,7,8. Furthermore, some of these toxins can 
cause health effects through their presence in sea spray aerosols. This has been reported for brevetoxins which is 
a group of toxic cyclic polyethers produced by the dinoflagellate Karenia brevis among others9. Exposure to aer-
osolized brevetoxins can lead to respiratory symptoms in humans during algal bloom conditions, particularly in 
people with asthma10,11. The effects of brevetoxins have been well-studied and documented6,9–11.
Little attention has, however, been given to other phycotoxins and to their potential effects at the low, envi-
ronmentally relevant, concentrations in which they may be present in sea spray aerosols (SSAs) during regular 
environmental conditions12. In addition, some of these bioactive molecules (e.g. yessotoxin)13 have been targeted 
for their pharmaceutical or biotechnological potential14,15. Yessotoxin, produced by marine dinoflagellates such 
as Protoceratium reticulatum, appears to induce apoptotic cell death through the mammalian target of rapamycin 
(mTOR) pathway16 and seems to inhibit tumor growth17. Combined with other unidentified biogenics in the 
marine environment, these known bioactive molecules could contribute to beneficial health effects in coastal 
environments. A number of studies highlight several health promoting pathways through which airborne micro-
biota and biogenics from blue and green environments may have beneficial health effects18,19. Airborne micro-
biota are thought to contribute to a more effective immuno-regulation once inhaled or ingested18. Additionally, 
it was suggested that inhalation of low levels of microbes and parasites reduces inflammation and improves 
immunoregulation18,20. Biogenics, i.e. natural chemicals produced by plants, fungi, phytoplankton species and 
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bacteria1,3,12, have been hypothesized to induce positive health effects via the interaction with specific cell sign-
aling pathways such as the mTOR pathway19. The mTOR pathway is a key regulator of cell growth and cell pro-
liferation that integrates signals from both the environment (e.g. nutrients) and internal processes (e.g. energy 
status, growth factors) to regulate several cellular processes including autophagy and energy metabolism21. The 
link between the mTOR pathway and beneficial health effects is supported by a large number of studies22–26, 
demonstrating that inhibition of this cell signaling pathway is associated with health benefits such as anti-cancer 
and anti-inflammatory effects.
Here, we hypothesize that beneficial health effects of SSAs in coastal environments can be attributed to inter-
actions between marine biogenics such as yessotoxin and the mTOR pathway. To this end, we exposed human 
epithelial lung cells to extracts of (1) the pure bioactive molecule homoyessotoxin (hYTX), (2) a SSA generated in 
a laboratory tank inoculated with the homoyessotoxin producing dinoflagellate Protoceratium reticulatum27, (3) a 
natural SSA collected at the seashore, and (4) a chemical inhibitor of the mTOR pathway (Torkinib/PP242). In our 
design, we start from the simplest situation: the exposure to one biogenic molecule (hYTX) as a single substance 
and extrapolate to a more complex but characterized laboratory generated sample and finally to a black-box 
environmental mixture (i.e. natural SSA). We used RNA sequencing to characterize the molecular responses. The 
different treatments, including different dose levels per treatment, allowed us to study a range of conditions, from 
most realistic, i.e. natural SSA, to the simplest, i.e. a single biogenic molecule (hYTX). With this experimental 
design, we will address the following research questions: (1) the effects of pure hYTX as shown in previous studies 
are similar to the effects of a SSA extract generated using a laboratory aerosol tank inoculated with a hYTX pro-
ducer at the same hYTX dose levels, (2) the effects of a SSA extract generated using a laboratory aerosol tank can 
be extrapolated to effects of a natural SSA collected at the seashore at more environmentally realistic dose levels 
and (3) hYTX, a SSA extract generated in the lab and a natural collected SSA extract all interact with the mTOR 
pathway in human lung cell lines. As such, we aim to provide molecular evidence to support the hypothesis that 
SSAs are a source of health benefits such as anti-cancer, positive cardiovascular and anti-inflammatory effects.
Results
We quantified the expression of 16,5654 genes and observed differential expression across all treatments. The 
highest number of differentially expressed (DE) genes was observed in the pure homoyessotoxin treatment, here-
after referred to as hYTX. We observed a decreasing number of differentially expressed genes in the chemical 
inhibitor treatment, hereafter referred to as mTOR inhibitor, the natural SSA treatment and the treatment with a 
SSA generated using a laboratory aerosol tank, hereafter referred to as labSSA. We observed significant DE genes 
in all treatments at the highest dose levels at false discovery rates (FDR) of 0.01 and 0.05 (Fig. 1A). Given the small 
difference between the two FDRs, the most conservative FDR was selected for further analysis. We identified two 
DE genes shared by all high dose level treatments and the mTOR inhibitor (Fig. 1B) and three DE genes shared 
by all high dose level treatments. The two DE genes shared by all (high dose level) treatments and the mTOR 
inhibitor (Fig. 1B) were the small integral membrane protein 29 (SMIM 29) and proprotein convertase subtilisin/
kexin type 9 (PCSK9). The three genes shared by all high dose treatments but not with the mTOR inhibitor were 
stearoyl-CoA desaturase (SCD), cytochrome P450 family 1 subfamily B member 1 (CYP1B1) and peptidyl argi-
nine deiminase 3 (PADI3).
We observed a total of 1898 genes with a significant dose response effect across the three treatments (hYTX, 
lab SSA and natural SSA). Based on a regression analysis and clustering, we found four clusters of dose response 
patterns. These clusters all show the same trend which consists of a steep dose response curve for hYTX, while 
the lab SSA and the natural SSA show a slower increase (Fig. S2). A pathway analysis revealed four pathways that 
were enriched for genes with a significant dose response effect (Table S3). These pathways are the spliceosome, 
lysosome, steroid biosynthesis and glycogenesis.
A comparison of the effects of hYTX and the effects of a SSA extract generated in the lab on gene 
expression. First, we observed that all DE genes regulated by the lab SSA are a subset of the DE genes regulated 
by hYTX (Fig. 1B). Second, for the five genes shared by the lab SSA, hYTX and the natural SSA (Figs 1B and 2), 
Figure 1. Differential gene expression across treatments. (A) Number of significant genes at different false 
discovery rates (FDR) for the different sea spray aerosols (SSA) treatments and homoyessotoxin (hYTX). (B) 
Venn diagram of shared significant genes across high dose treatments with significant genes at an FDR of 0.01.
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we see the same dose response pattern for both the hYTX and the lab SSA treatment: increasing gene expression 
with increasing dose. For SMIM 29, the responses to the highest dose (0.5 µg L−1) of both the hYTX and lab SSA 
treatments were comparable to the increased expression observed for the mTOR inhibitor treatment (Fig. 2A). 
In contrast, PCSK9 was downregulated by the mTOR inhibitor treatment while it was significantly upregulated 
at 0.5 µg L−1 of hYTX in both the hYTX and lab SSA treatments (Fig. 2B). The three other genes were not signifi-
cantly regulated by the mTOR inhibitor treatment (Fig. 2C–E).
Third, at the pathway level, we observed an increase in upregulated genes and a decrease in downregulated 
genes with increasing dose levels of the hYTX treatment for all pathways (Fig. 3). For the lab SSA treatment, this 
same pattern was observed for the lysosome and steroid biosynthesis but not for the glycogenesis and the splice-
osome (Fig. 3). For the glycogenesis and the spliceosome, more upregulated genes in the highest and lowest dose 
Figure 2. Differential gene expression in the pure homoyessotoxin treatment (hYTX, grey), the laboratory 
generated sea spray aerosol treatment (Lab SSA, blue) and mTOR inhibitor treatment (red). Log fold change for 
(A) small integral membrane protein 29 (SMIM 29), (B) Proprotein convertase subtilisin/kexin type 9 (PCSK9), 
(C) stearoyl-CoA desaturase (SCD), (D) cytochrome P450 family 1 subfamily B member 1 (CYP1B1) and (E) 
peptidyl arginine deiminase 3 (PADI3). Stars denote significant gene expression at a false discovery rate of 0.01.
Figure 3. Dose response patterns in significantly affected pathways. Number of significantly upregulated (>0) 
or downregulated (<0) genes in (A) the glycogenesis, (B) spliceosome, (C) lysosome, (D) steroid biosynthesis 
for the treatments: homoyessotoxin (hYTX, grey), the lab sea spray aerosol (SSA, blue), and the mTOR inhibitor 
(red).
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treatment was observed while the mid dose treatment showed more down regulated genes (Fig. 3A,B). For three 
of the four pathways, the mTOR inhibitor treatment response was similar to the low dose of both the lab SSA and 
hYTX treatments (Fig. 3A,C,D). For the spliceosome, the response differed (Fig. 3B).
A comparison of the effects of the SSA extract generated in the lab and the extract of a natural 
SSA on gene expression. We observed 5 DE genes that were shared between the lab SSA and the natural 
SSA treatments and these 5 genes were also shared with the pure hYTX treatment (Figs 1B and 4). A direct 
comparison between the natural and the lab SSA can be made in terms of total mass of the sampled aerosol by 
using the sodium cation as a proxy for this28. The lab SSA dose levels are 2.8 µg Na+ well−1, 0.06 µg Na+ well−1 and 
0.00006 µg Na+ well−1 while the natural SSA dose levels, due to the smaller sample size, were 0.6 µg Na+ well−1, 
0.14 µg Na+ well−1 and 0.014 µg Na+ well−1 (section 1.2). As such, the high dose natural SSA treatment is almost 
five times smaller, in terms of aerosol mass, than the high dose lab SSA treatment. This is due to the fact that the 
levels of the natural SSA were sampled and selected to represent different realistic exposure scenarios whereas 
the lab SSA levels were sampled and selected to cover the complete dose response curve of hYTX. The low dose 
natural SSA can therefore be situated between the low and mid dose lab SSA while the mid and high dose natural 
SSA can be situated between the mid and high dose lab SSA.
For three genes (i.e. SMIM29, CYP1B1, PADI3), the pattern was the same for both treatments with an 
increased gene expression with increasing dose levels (Fig. 4A,D,E). The two other significantly affected genes (i.e. 
PCSK9 and SCD), showed a different pattern between these two treatments (Fig. 4B,C). We observed an increased 
gene expression with increasing dose levels for the lab SSA but a decreased gene expression with increasing dose 
levels for the natural SSA (Fig. 4). The mTOR inhibitor showed the same response pattern as the highest dose 
treatment of the natural SSA, which was for mTOR significant for both PCSK9 and SMIM29 (Fig. 4A,B).
At the pathway level, we studied the four pathways with a significant dose response pattern: glycogenesis, 
lysosome, spliceosome and steroid biosynthesis. Overall, we observed different patterns for the two treatments 
across the four pathways (Fig. 5). For example, for the steroid biosynthesis, we observed more upregulation with 
increasing dose levels for the lab SSA and more downregulation with increasing dose levels for the natural SSA. 
In all pathways, the response of the mTOR inhibitor treatment was comparable to the response of the natural SSA 
(Fig. 5).
All treatments interact with the mTOR regulatory pathway. Here, the genes of the mTOR pathway 
(as defined by the KEGG database)29 and a hallmark set of genes upregulated upon activation of the mTORC1 
complex (as defined by the molecular signature databases)30 were used to evaluate potential effects of the treat-
ments on the mTOR pathway. No enrichment of significantly expressed genes of the mTOR pathway (as defined 
by the KEGG database) was observed in any of the treatments. However, individual genes of the mTOR path-
way (as defined by the KEGG database), were significantly regulated in different high dose treatments, with the 
exception of the lab SSA for which no genes were differentially expressed (Table S1). Taking a closer look at 
the hallmark mTORC1 set, we observed that the gene expression patterns differed across treatments (Fig. S1). 
Hierarchical clustering of these patterns indicated that differentially expressed genes were in general regulated 
Figure 4. Differential gene expression in the laboratory generated sea spray aerosol treatment (Lab SSA, blue), 
the natural SSA treatment (yellow) and mTOR inhibitor treatment (red). Log fold change for (A) small integral 
membrane protein 29 (SMIM 29), (B) Proprotein convertase subtilisin/kexin type 9 (PCSK9), (C) stearoyl-CoA 
desaturase (SCD), (D) cytochrome P450 family 1 subfamily B member 1 (CYP1B1) and (E) peptidyl arginine 
deiminase 3 (PADI3). Stars denote significant gene expression at a false discovery rate of 0.01.
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in the opposite direction for hYTX and the lab SSA versus the natural SSA and the chemical inhibitor (Fig. S1). 
This pattern is even more prominent when focusing on the genes that contribute significantly (FDR < 0.05) to 
the enrichment score in the hallmark set for all 4 treatments (Fig. 6). This group of 17 genes showed completely 
opposite regulation patterns in the high dose hYTX and high dose lab SSA versus the high dose natural SSA and 
the chemical inhibitor (Fig. 6). The first group showed increased expression or upregulation of hallmark genes, 
confirmed by a significant positive enrichment score of 2.14 and 1.92 for the pure hYTX and lab SSA treatments 
respectively (Table S2). In contrast, the chemical inhibitor and high dose natural SSA treatments showed an inhi-
bition of expression or downregulation of the hallmark genes, reflected by a negative enrichment score of −2.32 
and −1.24 for the mTOR inhibitor and the natural lab SSA treatment respectively (Table S2).
Discussion
It has been postulated that biogenic molecules in SSAs lead to beneficial health effects in humans through inter-
actions with the mTOR pathway19. Here, we report the effects of a pure biogenic molecule hYTX, the extract of a 
lab generated SSA (containing hYTX from an algal producer) and the extract of a natural SSA sampled from the 
environment on human lung cells.
We observed a high overlap between the effects of the pure hYTX and the lab SSA treatments at the gene and 
pathway level. This suggests that the effects of the lab SSA are most likely comparable to effects of a diluted hYTX 
treatment. Or, in other words, the effects of the lab SSA containing hYTX from an algal producer are weaker than 
the effects of the pure hYTX treatment despite containing the same amount of hYTX. This suggest that (1) the lab 
SSA may contain additional molecules which interact with hYTX leading to weaker effects or that (2) the lab SSA 
may contain hYTX or YTX analogues or metabolites with potential weaker effects that compete with hYTX for 
molecular binding sites and uptake. Both assumptions suggest a lower bioavailability of pure hYTX, potentially 
leading to a lower actual dose.
Interestingly, the effects of the natural SSA at the gene and pathway level closely resemble the effects of the 
mTOR inhibitor, but contrast with the effects of hYTX and the lab SSA. The differences between these two treat-
ment clusters highlight that while all treatments target the mTOR pathway, their effects are opposite. This suggests 
that the natural SSA is a complex mixture of biogenics interacting with the mTOR pathway leading to different 
expression patterns of the same pathway than the lab SSA. Literature reports only briefly on the organic composi-
tion of SSAs, but suggests a large diversity in biogenic compounds31,32. The similarities in regulation of the mTOR 
pathway between the natural SSA and the chemical inhibitor suggest that natural SSAs contain molecules that 
cause similar effects on the mTOR pathway as the chemical inhibitor. The differences between the lab SSA and 
the natural SSA could be related to the differences in doses or the presence of other or additional unknown mole-
cules. The high dose treatment for both hYTX and the lab SSA of 0.5 µg hYTX liter−1 is an extreme case scenario, 
reflecting concentrations in water during harmful algal blooms (supportive information 1.2). The environmental 
(background) concentrations of hYTX in water and air have not been previously reported but are expected to lie 
between the low and mid dose levels based on estimates of cell counts of hYTX producers and hYTX production 
per cell (supportive information 1.2). As such, it is clear that while the exact regulation of genes and pathways 
differs between lab SSA and natural SSA extracts, both samples significantly interact with the mTOR pathway. 
Furthermore, the effects of the natural SSA extract are similar to the effects of the chemical mTOR inhibitor sug-
gesting beneficial health effects at environmentally relevant concentrations.
Figure 5. Dose response patterns in significant pathways. Number of significantly upregulated (>0) or 
downregulated (<0) genes in (A) the glycogenesis, (B) the spliceosome, (C) lysosome, (D) steroid biosynthesis 
for the treatments: lab sea spray aerosol (SSA, blue), natural SSA (yellow) and mTOR inhibitor (red).
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We observed two genes significantly regulated by all treatments and by the mTOR inhibitor. The first gene 
was the small integral membrane protein 29 (SMIM 29). Little functional information on this protein is available, 
although it is ubiquitously expressed in at least 25 tissues33. The other gene is proprotein convertase subtilisin/
kexin type 9 (PCSK9), primarily involved in lipid homeostasis and apoptosis34. PCSK9 is thought to have two 
major functions: (1) maintenance of lipid homeostasis by the regulation of low-density lipoprotein receptors and 
(2) the regulation of neural apoptosis34. In general, the overexpression or upregulation of PCSK9 is associated 
with the dysregulation of pathways involved in the cell cycle, inflammation and apoptosis while the inhibition or 
downregulation of PCSK9 in carcinogenic lung cells has been associated with apoptosis of these cell lines34. In 
mouse, a similar pattern has been observed35. Upregulation of PCSK9 was associated with multi-organ pathology 
and inflammation while PCSK9 downregulation was associated with protection against inflammation, organ 
pathology and systemic bacterial dissemation35. These findings in literature together with our results, (i.e. down-
regulation of PCSK9 in the mTOR inhibitor and the natural SSA treatments) suggest beneficial health effects of 
natural SSAs through the apoptosis of lung cancer cells. Based on the results provided here on PCSK9, we propose 
that SSAs contain molecules with significant pharmaceutical potential in targeting PCSK936.
We also observed three genes that were significantly regulated by all treatments but not by the mTOR inhibi-
tor: SCD, PADI3 and CYP1B1. The pattern of SCD was comparable to that of PCSK9 while the patterns of PADI3 
and CYP1B1 were comparable to the pattern of SMIM29. This can be attributed to the functions of SCD and 
PCSK9, as both are involved in lipid biosynthesis. Furthermore, research has already indicated links between 
the mTOR pathway and the lipid homeostasis37, including the effects on SCD and other genes after exposure to 
mTOR inhibitors37. Evidence points to the sterol regulatory element binding transcription factor 1 (SREBF1) 
through which the regulation of lipogenesis by mTOR is achieved37. This gene was significantly regulated by the 
natural SSA treatment, but not by any of the other treatments. CYP1B1 is commonly involved in the metabolism 
of xenobiotics and could play a role in metabolizing some of the biogenic molecules. Literature has also reported a 
relation between CYP1B1 and SCD in lipid homeostasis in liver cells38, although the extent of this relation in lung 
cells remains unclear. Here we observed an increase in expression of CYP1B1 in all treatments. Overexpression 
Figure 6. Enrichment of the mTOR Hallmark set. Heatmap for all treatments of the fold changes of genes that 
contribute significantly to the enrichment score for all three treatments at the highest dose and the mTOR inhibitor. 
Treatments: chemical inhibitor, homoyessotoxin (hYTX), lab sea spray aerosol (lab SSA) and natural sea spray 
aerosol (SSA) at high, mid and low doses. For hYTX and the labSSA hYTX levels are: 0.5 µg L−1 (high), 0.01 µg L−1 
(mid), 0.00001 µg L−1 (low). For the lab SSA, sodium levels are: 2.8 µg Na+ well−1(high), 0.06 µg Na+ well−1(mid), 
and 0.00006 µg Na+ well−1(low), and for the natural SSA, sodium levels are: 0.6 µg Na+ well−1(high), 0.14 µg Na+ 
well−1 (mid) and 0.014 µg Na+ well−1(low).
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of CYP1B1 has also been reported in lung cell lines through the aryl hydrocarbon receptor39, but no significant 
effects for this receptor were observed in any treatment of our study (Table S4). This suggests that the overex-
pression of CYP1B1 is more likely related to the regulation of SCD. In addition, PADI3 was also upregulated in 
all three high dose treatments (hYTX, lab SSA and natural SSA). PADI3 is generally not expressed in lung cells33 
and is primarily expressed in epidermis cells and keratinocytes40. Its function in lung cell lines remains unclear.
At the pathway level, we observed differential expression of genes linked to the mTOR pathway in all three 
high dose treatments (natural SSA, lab SSA, and hYTX). Our results also indicated significant effects on the 
mTOR pathway, but the effects and the potential beneficial health effects differ across treatments. Most likely, 
the effects on these genes are caused by the primary effects on the mTOR pathway. Furthermore, for three genes, 
these effects while linked to the mTOR pathway, are not observed with the mTOR inhibitor. This suggests that 
the effects of these experimental treatments (natural SSA, lab SSA, and hYTX) extend beyond the inhibition of 
mTOR but are related to or initiated by the effects on the mTOR pathway.
We observed four pathways that were significantly affected by the different treatments: glycogenesis, lysosome, 
spliceosome and steroid biosynthesis. For the steroid biosynthesis, these results are not surprising given the links 
that have already been discussed above between mTOR and lipid biosynthesis. In addition to steroid biosynthesis, 
the lysosome and glycogenesis also have links to mTOR. The inhibition of the mTOR pathway is known to activate 
protein degradation and autophagy through among others the lysosome41,42. The spliceosome has been proposed 
as a therapeutic target in cancer cells to inhibit mTOR, which leads to autophagy43. Specifically, depletion of small 
nuclear ribonucleoprotein polypeptide E (SNRPE) led to reduced cell viability in lung cancer cell lines. Here, we 
observed in addition to dose response effects for the spliceosome, a significant downregulation of SNRPE in the 
highest hYTX treatment but not in any of the other treatments (Table S5). Overall, the pathways with significant 
dose response effects can all be indirectly linked to the mTOR pathway, suggesting that the effects here are a 
consequence of the effects on the mTOR pathway, which most likely induces a cascade of events and interactions 
with other pathways.
Overall, the results at the gene level and at the pathway level highlight that the effects are primarily medi-
ated or linked through the mTOR pathway supporting the biogenesis hypothesis postulated by Moore19 that 
marine airborne biogenics interact with the mTOR pathway leading to health benefits. All treatments significantly 
affected the mTOR pathway, but we observed differences in the direction of the regulation of this pathway (Fig. 7). 
Furthermore, significant genes and enriched pathways across treatments all interact with mTOR, indicating that 
marine biogenics trigger a cascade of events through interaction with the mTOR pathway (Fig. 7). Thus, the 
effects of marine airborne biogenics are not limited to the mTOR pathway but include a cascade of genes and 
pathways involved in different metabolic processes (e.g. steroid biosynthesis, lysosome) with key links to mTOR 
(Fig. 7).
Methods
Culturing of A549 cells. Adenocarcinoma alveolar basal cell lines (A549) were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM), supplemented with 10% fetal bovine serum and 100 units.mL−1 penicil-
lin-streptomycin at 37 °C, 5% CO2 and >95% relative humidity. Confluent cell cultures (after 2–3 days) were 
passaged via trypsination (0.5% trypsin-EDTA) and split in a ratio of 1:6.
Experimental procedure. Confluent cell cultures were trypsinized and transferred in 3 mL fresh DMEM 
to Nunc 6-well multiplates at a density of 320,000 cells.well−1. After seeding, cells were incubated for 10 hours at 
37 °C, 5% CO2 and >95% relative humidity to stimulate growth and adherence to the surface. Then, cells were 
subjected to one of five treatments and were then incubated for another 43 hours at identical conditions prior 
to RNA extraction. The five treatments included (1) unexposed cell lines as a negative control, (2) an extract of 
a natural SSA sample from the seashore, (3) an extract of a laboratory generated SSA, (4) homoyessotoxin, (5) 
Figure 7. Molecular effects of marine aerosolized biogenics. A schematic representation of the molecular 
effects of sea spray aerosols observed within this study. Pathways are represented by ellipses, genes are 
represented by rectangles. Solid blue arrows represent interactions with a solid evidence base, dashed arrows 
represent hypothetical interactions observed, ⊢ represent inhibition.
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a chemical inhibitor of the mTOR pathway, i.e. Torkinib or PP242 (LC Laboratories), as a positive control. The 
negative control treatment also contained 2% methanol to exclude a solvent effect as all other treatments were 
extracted, diluted or dissolved in methanol. The chemical inhibitor treatment consisted of 0.3 µM of Torkinib 
or PP242. All aerosol samples were collected on a Whatman QM-A quartz microfiber filter using a membrane 
vacuum pump at the constant flow rate of 10 L min−1. The natural sea spray aerosol sample was collected at the 
waterline close to Ostend, Belgium (51°14′27″N, 2°56′10″E) by sampling for 46 minutes at a flow of 10 L min−1, 
which corresponds to the minute ventilation of an average human in rest (9–10 L min−1)44,45. During sampling, 
the wind direction was 0.7 ± 3.1° (North) and wind speed was 15.0 ± 0.6 m s−1, indicating white cap SSA produc-
tion. The detailed sampling and extraction procedure is described in supportive information 1.1. The lab SSA 
was obtained by inoculating a marine aerosol reference tank46 with 106 cells L−1 of Protoceratium reticulatum, 
a hYTX producer (SCCAP K-1474), and by collecting the generated SSA at a flow of 10 L min−1 for 16 hours to 
obtain sufficient material for further experiments and analysis. The detailed procedure is described in supportive 
information 1.1. Filters of the natural SSA and lab SSA were extracted following the same methanol extrac-
tion procedure. Certified reference material of hYTX was commercially obtained (National Research Council 
Canada) as a liquid with a concentration of 5 µM hYTX dissolved in methanol. This reference material was fur-
ther diluted in methanol to obtain the following dose levels: 0.5 µg L−1 (high), 0.01 µg L−1 (mid), 0.00001 µg L−1 
(low). Concentrations of hYTX in the lab SSA were measured using ultra-high-performance liquid chromatog-
raphy high-resolution Orbitrap mass spectrometry following procedures as reported by Orellana et al.47. To allow 
an optimal comparison between the hYTX treatment and the lab SSA, the lab SSA dose levels were determined 
based on the measured hYTX in these samples and the same dose levels as the hYTX treatment were selected 
(0.5 µg L−1 (high), 0.01 µg L−1 (mid), 0.00001 µg L−1 (low)). For the natural SSA, low, mid and high doses were 
determined by comparing the total alveolar surface of human lungs with the cell surface available in a single well 
(9.6 cm²) and comparing the sample collection duration (46 min) and experimental exposure duration (43 h), see 
supportive information 1.2. We selected a low dose that represents the same exposure as the amount of inhaled 
SSA during the sampling period at the seashore but extended over a 43 h exposure period and normalized to the 
cell surface in a single well (detailed calculations are reported in supportive information, section 1.2). The mid 
and high dose represent a 10x and 40x concentration of the low dose level. These levels were specifically cho-
sen to adhere to environmentally realistic (background) concentrations. The mid dose level (10x concentration) 
was based on the hypothesis of increased minute ventilation during physical exercise which is reported to vary 
between 70–100 L min−1 for both continuous and intermittent exercise45,48,49. The high dose level (40x concentra-
tion) was selected based on the hypothesis of increased aerosolization (i.e. improved wind conditions) as well as 
activities at the shore line or at sea (e.g. swimming, sailing, windsurfing, ...). The detailed procedure is described 
in the supportive information, section 1.2.
RNA extraction, library preparation and sequencing. RNA was extracted using the Qiagen RNEasy 
kit following the manufacturer’s instructions including DNAse digestion. After RNA extraction, the concen-
tration and quality of the total extracted RNA was checked by using the ‘Quant-it ribogreen RNA assay’ (Life 
Technologies, Grand Island, NY, USA) and the RNA 6000 nano chip (Agilent Technologies, Santa Clara, CA, 
USA), respectively. Subsequently, 250 ng of RNA was used to perform an Illumina sequencing library preparation 
using the QuantSeq 3′ mRNA-Seq Library Prep Kits (Lexogen, Vienna, Austria) according to manufacturer’s 
protocol. During library preparation 14 PCR cycles were used. Libraries were quantified by qPCR, according to 
Illumina’s protocol ‘Sequencing Library qPCR Quantification protocol guide’, version February 2011. A high sen-
sitivity DNA chip (Agilent Technologies, Santa Clara, CA, US) was used to control the library’s size distribution 
and quality. Sequencing was performed on a high throughput Illumina NextSeq500 flow cell generating 75 bp 
single reads.
Data analysis. Per sample, on average 7.5 × 106 ± 1.6 × 106 reads were generated. First, these reads were 
trimmed using cutadapt50 version 1.15 to remove the “QuantSEQ FWD” adaptor sequence. The trimmed reads 
were mapped against the Homo sapiens GRCh38.89 reference genome using STAR51 version 2.5.3a. The RSEM52 
software, version 1.3.0, was used to generate the count tables. Differential gene expression analysis between 
groups of samples was performed using edgeR53. Genes with less than 1 cpm in less than 4 samples were dis-
carded, resulting in 16,546 quantifiable genes. Read counts were normalized using trimmed mean of M-values 
(TMM) followed by a pairwise comparison of treatments with the negative and positive control using an exact 
test53. Significantly differentially expressed (DE) genes were called at a false discovery rate of 0.01. Significant 
enrichment of KEGG pathways29 with DE genes was done using a fisher test and called at an adjusted p-value level 
of 0.01. Benjamini-Hochberg adjustment was used to account for multiple testing. Gene set enrichment analysis 
(GSEA) was conducted to detect enrichment in hallmark gene sets and genetic and chemical perturbations gene 
sets of the molecular signature database30. Enriched gene sets were identified at a false discovery rate of 0.01. A 
dose response analysis was performed with the maSigPro54 R package for each of the three treatments of algal 
toxins. In a first step a general linear model was built with the 3 treatments, 3 concentrations and the square of 
each of concentration. Statistical testing was done using the log-likelihood ratio statistic. Genes with a FDR < 0.05 
were considered significantly differential. In a second step, for each significant differentially expressed gene, an 
optimized regression model was created using stepwise backward regression. Exclusion of the quadratic term 
from the model was performed using a regression ANOVA, testing if the regression coefficients differ from 0 at a 
significance level of 0.05. Afterwards the goodness of fit, R², of each optimized regression model was computed. 
Genes with a goodness of fit greater than 0.8 were used in a hierarchical cluster analysis based on the correlation 
between the regression models of the genes.
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Data Availability
Raw and processed sequencing reads are deposited in GEO and available under accession number: GSE113144.
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